Real World Outcome Analysis for APAC High Risk Localized Prostate Cancer Patients Treated With Radical Prostatectomy and Perioperative Hormonal Therapy
Real World Outcome Analysis for APAC High Risk Localized Prostate Cancer Patients Treated With Radical Prostatectomy and Perioperative Hormonal Therapy
The purpose of this study is to evaluate the yearly conditional prostate-specific antigen (PSA) progression-free survival (PFS) probabilities in high-risk localized prostate cancer (HR LPC) participants following radical prostatectomy (RP) and perioperative hormonal therapies (that is, hormonal treatment before RP and / or after RP) over 5 years.
Inclusion Criteria:
Participants who have histologically confirmed adenocarcinoma of the prostate
Participants newly diagnosed between 1 January 2015 to 30 June 2017 (both dates inclusive)
Participants fulfil high-risk localized prostate cancer defined by national comprehensive cancer network (NCCN) prostate cancer guideline (2020 version 1) a. T3a or; b. Grade group 4 or Grade group 5 or; c. Prostate specific antigen (PSA) greater than (>) 20 nanograms per milliliter (ng/mL)
Participants must have received radical prostatectomy (RP) between 1 January 2015 and 30 June 2017
Participants must have received at least one perioperative hormonal therapy pattern as listed below:
greater than or equal to (>=) 3 months neoadjuvant hormonal therapy, duration between date of last dose and date of RP should be less than or equal to (<=) 2 months; and/or
>= 6 months adjuvant hormonal therapy, first dose started within 6 months of RP surgery
Exclusion Criteria:
Distant metastasis based on conventional imaging (clinical stage M1) at time of prostate cancer diagnosis